Alzheimers news and alzheimers widget

Avineuro Pharmaceuticals, Inc. announced today the completion of preclinical studies of AVN-101, a potent small molecule for treatment of Alzheimer's disease. These studies demonstrate that AVN-101 is safe and well tolerated, and that it has a favorable pharmacokinetic profile. Based on these and other results, Avineuro Pharmaceuticals, Inc. plans to advance AVN-101 into clinical trials in Q1 2009.

People with Alzheimer's disease who also have diabetes or high blood pressure may die sooner than people without such disorders, according to a study published in the November 4, 2008, issue of Neurology®, the medical journal of the American Academy of Neurology. The study involved 323 people who had no memory problems when first tested but later developed dementia. Memory tests and physical exams were then given every 18 months.

People with Alzheimer's disease who also have diabetes or high blood pressure may die sooner than people without such disorders, according to a study published in the November 4, 2008, issue of Neurology®, the medical journal of the American Academy of Neurology. The study involved 323 people who had no memory problems when first tested but later developed dementia. Memory tests and physical exams were then given every 18 months.

When we talk about decision-making capacity among people with Alzheimer's disease and other kinds of dementia, we're often thinking about the capacity to make choices about health care, finances, and...

November is National Alzheimer's Disease Awareness Month, which is a great opportunity to learn more about the disease and advocate for more Alzheimer's research and services. But it's also a...

The Alzheimer's Association is seeking 50,000 signatures for its Proclamation to the Next President. The proclamation details the urgency of finding a way to cure or prevent Alzheimer's disease before...

Title: CT Scan (Computerized Axial Tomography)Category: Procedures and TestsCreated: 12/31/1997Last Editorial review: 11/4/2008